A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
about
Emerging critical role of molecular testing in diagnostic genitourinary pathologyDesign and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA).'Image and treat': an individualized approach to urological tumorsComparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA).Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.Prostate specific membrane antigen- a target for imaging and therapy with radionuclides.Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigenBiorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells.Targeting the prostate-specific membrane antigen for prostate cancer therapy.Prostate-specific membrane antigen-based imaging.PET imaging in prostate cancer: focus on prostate-specific membrane antigenNovel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer.Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.Metal-Based PSMA Radioligands.HLA class II antigen presentation by prostate cancer cells.A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cellsDesign and synthesis of a siderophore conjugate as a potent PSMA inhibitor and potential diagnostic agent for prostate cancer.High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.Radiochemistry and Preclinical PET Imaging of 68Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen.Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized pros
P2860
Q27021371-BFBF4DFC-3402-41FC-978F-D418D3D32384Q33586706-6951C9FA-0ACB-41FA-99B5-D095211A76FAQ33792596-22CAB181-8153-414B-99D7-ABFBC93D866DQ35282416-B3744C9B-0766-4BE2-BB51-811077A64D4BQ35634016-E0836C08-CA36-4407-B537-C4B2749843EBQ35877470-2C7AEC46-3022-46FC-B512-A84524327FF7Q35902274-BE7AB336-B0FE-45DB-B9DB-284322569B53Q36010923-DFDB4C20-6568-4461-B4A7-0AC02381158DQ36135685-6CDAC219-27D3-4AB4-BDF7-EA099F277961Q36160805-3AB76D4F-40C8-4CBA-84D8-E45BC2C3F54CQ37183709-3693316A-C48F-467D-ABAD-F227B7BDAF04Q37218120-99F56F7D-C37A-4ED6-896C-37C02173C6A2Q37773273-103E7947-B8C9-4FB6-977F-5E8F53B65D7FQ38015617-51919500-3E4E-4E40-B229-E2895D2398E3Q38099369-2EF0274E-143F-40DF-8C4A-FF54D366D66EQ38699173-51376C82-92EE-4F93-B815-DB6F6CBBDE53Q38896408-35D94461-A129-4009-ACEB-A795E3CA737AQ39017235-83A19A65-B47E-45BA-B7A1-A45B71338741Q39198527-7293B0A6-DEBD-4F32-AE05-9C43F2A9E789Q40067331-892B9FC9-9C7F-4963-B2E7-7CE6C73A8C05Q42575116-8A1A327E-2449-4918-8F17-5C04624E61C7Q42789362-83CF9B76-D4B6-4F67-BBC4-D8741A778667Q44994966-14DC1CCA-9002-4826-8BBB-063F0AC187A3Q45753373-9D7A13A2-A6BA-432A-A105-9EEA5BFAD033Q54479089-B23649F0-D3DB-4BD1-9629-6AF887F5DF50
P2860
A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A new generation of monoclonal ...... targeting of prostate cancer.
@en
type
label
A new generation of monoclonal ...... targeting of prostate cancer.
@en
prefLabel
A new generation of monoclonal ...... targeting of prostate cancer.
@en
P2093
P356
P1433
P1476
A new generation of monoclonal ...... c targeting of prostate cancer
@en
P2093
Dorothee Gierschner
Patrick Bühler
Ulrich Wetterauer
Ursula Elsässer-Beile
Wolfgang Schultze-Seemann
P304
P356
10.1002/PROS.20367
P50
P577
2006-09-01T00:00:00Z